Canadian holding company Wittington Investments has agreed to acquire Boots in a US$8.9-billion transaction that will give the Weston family operational control of one of the United Kingdom’s largest pharmacy, health and beauty retailers.
Toronto-based Fairfax Financial Holdings is partnering with Wittington on the acquisition, with Wittington maintaining operational control. Galen Weston, chairman of Wittington, will become chairman of Boots upon closing, which is expected in the first quarter of 2027 subject to regulatory approvals and customary closing conditions.
The deal adds a major international retail platform to the Weston family’s holdings, and one with considerable parallels to a business it already knows well in Canada. Wittington is the controlling shareholder of George Weston Limited, which controls Loblaw Companies Limited, owner of Shoppers Drug Mart.
Boots is being acquired by Wittington, not Loblaw or Shoppers Drug Mart. No combination of the Canadian and British pharmacy businesses has been announced.
Boots Deal Includes Retail, Beauty and Healthcare Businesses
Wittington is acquiring Boots’ retail operations in the UK and Ireland, Boots Opticians, No7 Beauty Company, its Thailand operations and franchised businesses from The Boots Group, which is majority owned by Sycamore Partners in partnership with Stefano Pessina and his family.
Sycamore and the Pessina family will retain The Boots Group’s other interests, including Farmacias Benavides and Alliance Healthcare Deutschland. The transaction values the businesses being acquired at US$8.9 billion, including assumed debt.
Boots has more than 1,800 stores and over 50,000 employees, giving Wittington control of an extensive physical retail network across the UK and Ireland. The business also includes more than 4,700 registered pharmacists, a growing range of healthcare services, a substantial online operation and a large beauty business that includes No7 Beauty Company.
The acquisition follows a period of improved performance at Boots. For its fiscal year ended August 2025, Boots UK reported revenue of approximately £7.5 billion, while pre-tax profit increased by about 25 per cent to £337 million.
Boots had also recorded 17 consecutive quarters of comparable sales growth by the time Sycamore Partners completed its acquisition of Walgreens Boots Alliance in August 2025. Sycamore subsequently established Boots as a standalone company, with the Pessina family remaining invested alongside it.
Boots and Shoppers Drug Mart Have Striking Parallels
The strategic fit becomes clearer when Boots is compared with Shoppers Drug Mart, which Loblaw acquired in 2014 following a deal announced the previous year at approximately C$12.4 billion.
Shoppers today operates more than 1,300 pharmacy locations across Canada under banners including Shoppers Drug Mart and Pharmaprix. Its business spans prescription pharmacy, beauty, healthcare services, convenience retail and digital health, several of the same areas that are important to Boots.
Boots combines pharmacy with healthcare, beauty, convenience merchandise and digital services across a larger physical network. It has also been investing in redesigned healthcare areas and expanding the services available through its pharmacies and online platforms.
Wittington pointed to the Weston group’s experience in pharmacy-led retail as one of the strengths it brings to Boots. That experience gives the company familiarity with many of the categories and operating issues involved in Boots, even though the British retailer will sit outside Loblaw.
“Boots is one of Britain’s most enduring businesses, with a rich heritage, a trusted name and a vital role in everyday life across the UK and Ireland,” Weston said in announcing the acquisition.
“We see a meaningful opportunity to make a great business even better through stable long-term ownership, further capital investment, and the renewed operating focus required to serve customers with excellence for generations to come,” he said.
The Price Raises an Interesting Comparison
Retail strategist Carl Boutet said the price Wittington is paying is particularly interesting when compared with Loblaw’s acquisition of Shoppers Drug Mart more than a decade ago.
“In real terms, the Westons are paying roughly a quarter less for Boots than they paid for Shoppers, and they get a bigger store network,” Boutet said. “Is that a bargain? Only if they fix the estate and the economics of community pharmacy.”
The comparison is not exact. The Boots consideration includes assumed debt and is denominated in U.S. dollars, while the Shoppers transaction was announced in Canadian dollars more than a decade ago, making Boutet’s inflation-adjusted assessment more useful as a broad comparison than as a direct measure of relative valuation.
His comment also points to the work ahead. Boots offers enormous physical scale, but more than 1,800 stores also represent a significant estate to maintain, modernize and operate while the economics of community pharmacy remain an important consideration.
Wittington has already identified where some of its capital will go. The company said it intends to invest in upgrading Boots stores, improving its online experience and expanding healthcare services.
Boots has been doing some of that work already. More than 185 stores have redesigned beauty halls, while the company has also been modernizing healthcare areas in selected locations to bring pharmacy and other services together.
Healthcare Expands the Role of the Store
Boots says it offers around 180 healthcare services in stores and online, while its pharmacists have taken on a broader clinical role within the UK healthcare system. Its operations include vaccinations and other pharmacy services as well as Boots Online Doctor, Boots Opticians and related healthcare businesses.
Shoppers Drug Mart has been expanding its healthcare operations in Canada as well. Loblaw said its 2026 capital program includes 34 new Shoppers Drug Mart and Pharmaprix pharmacies and care clinics, part of a broader expansion of its pharmacy and healthcare network.
The operating environments differ considerably, particularly because of Boots’ relationship with the UK’s National Health Service and the funding environment for community pharmacies. Wittington’s experience with Shoppers does not remove those challenges, but it gives the company experience with a retail model in which stores increasingly serve both commercial and healthcare functions.
Boutet’s reference to community pharmacy economics is important in that context. Growing healthcare services can create additional opportunities for Boots, but the returns will depend in part on the economics of delivering those services across such a large network.
Beauty Adds an Existing Canadian Connection
Beauty is another significant part of the Boots business. The retailer has upgraded more than 185 beauty halls and expanded its assortment of prestige brands, while No7 Beauty Company is included in the businesses being acquired by Wittington.
No7 already has a Canadian presence through Shoppers Drug Mart, which sells the British brand’s skincare and cosmetics products. Some No7 products are marketed by Shoppers as exclusives, creating an existing commercial relationship between the Canadian retailer and a company that will come under Wittington ownership.
No changes to No7’s Canadian distribution have been announced, and there is no indication that Wittington intends to combine the beauty operations of Boots and Shoppers. The existing relationship does, however, provide another direct connection between the businesses beyond their similar retail models.
Weston Family Returns to Major British Retail Ownership
The acquisition marks a significant return to British retail ownership for the Weston family. Wittington previously controlled Selfridges, acquiring the British department store in 2003 and later building a broader luxury department-store group before selling the business roughly two decades later.
Boots is a very different retail platform, with more than 1,800 stores serving everyday pharmacy, health and beauty needs. Wittington’s Selfridges history provides experience owning a major British retailer, while the Weston group’s involvement with Shoppers Drug Mart offers a closer operating comparison for the business it is acquiring now.
Fairfax adds another Canadian component to the transaction. The Toronto-based company has investments in consumer businesses including Sleep Country and Sporting Life Group, although Wittington will retain operational control of Boots.
Fairfax chairman and CEO Prem Watsa said he expects Wittington to be a strong long-term owner, pointing specifically to the Weston family’s experience in Canadian pharmacy and beauty retail. The companies have not disclosed the precise economic ownership split between Wittington and Fairfax in the acquisition.
Boots Changes Hands Again
The transaction comes relatively soon after Boots was separated from Walgreens Boots Alliance. Sycamore Partners completed its acquisition of Walgreens Boots Alliance in August 2025 and established Boots as a standalone company, allowing its management to focus on the British-led business separately from Walgreens and other former WBA operations.
The US$8.9-billion agreement with Wittington comes little more than a year after that restructuring. Boots is now moving to an owner that says it intends to provide long-term ownership and additional capital, with store investment, digital improvements and healthcare expansion already identified as priorities.
The Weston group brings considerable experience in pharmacy-led retail, but the economics of the Boots business will determine whether the acquisition ultimately proves attractive. Store productivity, the capital required to modernize the estate, continued momentum in beauty and the economics of community pharmacy will all influence the return Wittington generates from its investment.
The transaction is expected to close in the first quarter of 2027. If approved, Galen Weston will take the chairman’s role as Wittington begins investing in a 177-year-old British retailer with one of the country’s largest pharmacy networks.
